Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

• Post author:andrewkaretas
• Post published:October 18, 2020
• Post category:FLT3/Scientific Publications

Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

American Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia

• Post author:andrewkaretas
• Post published:December 18, 2019
• Post category:FLT3/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2019 – Preclinical Evaluation of ALLO-819, Targeting FLT3, in Acute Myeloid Leukemia

American Society of Hematology (ASH) Dec. 2018 – ALLO-819, An Allogeneic FLT3 CAR T Therapy Possessing An Off-Switch for the Treatment of Acute Myeloid Leukemia

• Post author:andrewkaretas
• Post published:December 18, 2018
• Post category:FLT3/Scientific Publications

Continue ReadingAmerican Society of Hematology (ASH) Dec. 2018 – ALLO-819, An Allogeneic FLT3 CAR T Therapy Possessing An Off-Switch for the Treatment of Acute Myeloid Leukemia